What are impacts of SK and Hanmi’s ‘low-volume Xarelto generic’ approvals?
SK Chemicals and Hanmi Pharm which succeeded in developing the first generics of the novel oral anticoagulant(NOAC), Xarelto, acquired the low volume and entire volumes respectively.
Particularly, since the two companies were confirmed to apply the minimum volume, 2.5mg, for the ‘prioritized sal...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
